Skip to main content

Table 2 Detailed clinical parameters of enrolled SSc patients

From: Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity

Sample ID Sex (F/M) Disease duration (years) Auto-antibody profile NVC pattern (E/A/L) Skin involvement (lcSSc/dcSSc) ILD (Yes/No) GI involvement (Yes/No) PAH (Yes/No) Renal involvement (Yes/No) DUs (Yes/No) FVC DLCO
SSc1 F 23 Scl70 L dcSSc Yes Yes Yes Yes Yes 77 44
SSc2 F 23 Scl70 L lcSSc Yes Yes Yes No Yes / /
SSc3 F 16 Scl70 A lcSSc Yes Yes Yes No Yes 88 93
SSc4 F 14 Scl70 A lcSSc Yes No No Yes No 97 53
SSc5 F 4 Scl70 L dcSSc Yes No No No Yes 108 70
SSc6 F 11 CENP-A/B A lcSSc No No No Yes No 85 85
SSc7 F 3 CENP-A/B A lcSSc No No No Yes No 110 97
SSc8 F 15 CENP-A/B A lcSSc No Yes No Yes No 119 75
SSc9 M 13 Scl70 E lcSSc Yes No No Yes No 93 90
SSc10 F 2 CENP-A/B A lcSSc Yes Yes No Yes No 113 91
SSc11 F 16 Scl70 L dcSSc Yes Yes No No Yes 26 27
SSc12 M 6 Scl70 A lcSSc Yes Yes No No Yes 74 92
SSc13 F 1 Scl70 L lcSSc Yes Yes No No Yes 68 47
SSc14 F 4 CENP-A/B L dcSSc No Yes No No Yes 52 /
SSc15 F 4 CENP-A/B A lcSSc No No No No No 119 142
SSc16 F 4 CENP-A/B E lcSSc No No No No Yes 103 93
SSc17 F 7 CENP-A/B A lcSSc No Yes No Yes No 93 102
SSc18 F 9 Scl70 A lcSSc Yes Yes Yes Yes Yes 86 47
  1. Detailed clinical parameters of each enrolled SSc patient. Data include disease duration; autoantibody profile: anti-topoisomerase I (Scl70) antibodies, and anti-centromere antibodies polypeptides A and B (CENP-a and CENP-B); pattern of microangiopathy at nailfold videocapillaroscopy (NVC); “limited” (lcSSc) and “diffuse” (cdSSc) cutaneous skin involvement, gastrointestinal (GI) and renal involvements; presence of interstitial lung disease (ILD); pulmonary arterial hypertension (PAH); digital ulcers (DUs); forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO)
  2. The sign “/” indicates that patients was unable to complete the functional test